The stock has a 36-month beta value of 1.74. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 4 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for COGT is 88.93M, and at present, short sellers hold a 8.21% of that float. On December 27, 2024, the average trading volume of COGT was 1.38M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
COGT) stock’s latest price update
Cogent Biosciences Inc (NASDAQ: COGT)’s stock price has gone rise by 0.13 in comparison to its previous close of 7.86, however, the company has experienced a 3.01% increase in its stock price over the last five trading days. benzinga.com reported 2024-12-09 that On Sunday, Cogent Biosciences, Inc. COGT revealed updated clinical results from the Open Label Extension (OLE) portion of the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis.
COGT’s Market Performance
COGT’s stock has risen by 3.01% in the past week, with a monthly drop of -14.36% and a quarterly drop of -27.80%. The volatility ratio for the week is 5.18% while the volatility levels for the last 30 days are 7.13% for Cogent Biosciences Inc. The simple moving average for the past 20 days is -9.01% for COGT’s stock, with a -12.26% simple moving average for the past 200 days.
Analysts’ Opinion of COGT
Robert W. Baird, on the other hand, stated in their research note that they expect to see COGT reach a price target of $8, previously predicting the price at $14. The rating they have provided for COGT stocks is “Neutral” according to the report published on February 26th, 2024.
Citigroup gave a rating of “Buy” to COGT, setting the target price at $11 in the report published on February 08th of the current year.
COGT Trading at -20.30% from the 50-Day Moving Average
After a stumble in the market that brought COGT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.59% of loss for the given period.
Volatility was left at 7.13%, however, over the last 30 days, the volatility rate increased by 5.18%, as shares sank -18.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.56% lower at present.
During the last 5 trading sessions, COGT rose by +3.01%, which changed the moving average for the period of 200-days by +23.94% in comparison to the 20-day moving average, which settled at $8.65. In addition, Cogent Biosciences Inc saw 33.84% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for COGT
Current profitability levels for the company are sitting at:
- -46.61 for the present operating margin
- 0.47 for the gross margin
The net margin for Cogent Biosciences Inc stands at -43.36. The total capital return value is set at -0.79. Equity return is now at value -78.47, with -65.53 for asset returns.
Currently, EBITDA for the company is -205.86 million with net debt to EBITDA at 0.31. When we switch over and look at the enterprise to sales, we see a ratio of 141.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.44.
Conclusion
To sum up, Cogent Biosciences Inc (COGT) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
